Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, in Vivo Active KRASG12CInhibitor

Abstract

Activating mutations in KRAS are the most frequent oncogenic alterations in cancer. The oncogenic hotspot position 12, located at the lip of the switch II pocket, offers a covalent attachment point for KRASG12Cinhibitors. To date, KRASG12Cinhibitors have been discovered by first covalently binding to the cysteine at position 12 and then optimizing pocket binding. We report on the discovery of the in vivo active KRASG12Cinhibitor BI-0474 using a different approach, in which small molecules that bind reversibly to the switch II pocket were identified and then optimized for non-covalent binding using structure-based design. Finally, the Michael acceptor containing warhead was attached. Our approach offers not only an alternative approach to discovering KRASG12Cinhibitors but also provides a starting point for the discovery of inhibitors against other oncogenic KRAS mutants.